Jan. 10 at 5:40 PM
$IOBT Even dog like
$MREO is bouncing back bc most notably some funds have taken a stake and final p3 data is yet to be presented. Anyway, this is another reason I think
$IOBT has good chance at funding and BO (latter, less likely imo ) because there's money that's being allocated by funds and Big Pharma has been active in M&A, finally addressing patent cliff concerns. Mind you,
$IOBT isn't the primary focus of BPs at the moment but there's been some notable smaller deals of late.. peak sale for Cylembio is around 500m/yr. P3 will take 2 years? Ave cost per enrollee is roughly 100k. They enrolled around 400, maybe they double that in P3 to 800.. that's 80m. So round up to 100m? Administrative and other cost another 50m? so all in on P3 will take around 150m or so is my guess. I think r/r proposition is favorable.
